Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation.Am J Hematol.(2019).
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.Lancet Haematol.(2019).
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.Am J Hematol.(2019).
Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation.Acta Haematol1-9.(2019).
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.N Engl J Med380, 1628-1637.(2019).
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.Cancer.(2016).
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.Blood.(2016).
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.Oncotarget.(2016).
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.Clin Lymphoma Myeloma Leuk.(2015).
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia.Haematologica.(2015).
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.Lancet Haematol2, e186-93.(2015).
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.Cytometry A.(2015).
Reversal of Acquired Drug Resistance in FLT3-mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies.Clin Cancer Res.(2014).
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia.N Engl J Med371, 1005-1015.(2014).
CL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.Blood.(2013).
Targeting hypoxia in the leukemia microenvironment.Int J Hematol Oncol2, 279-288.(2013).